Rosen Law Firm has filed a class action lawsuit on behalf of Ardelyx stock purchasers between January and August 2026. The suit alleges Ardelyx made false and misleading statements about the commercial performance and growth prospects of its drugs XPHOZAH and IBSRELA, particularly regarding payer access and reimbursement barriers that slowed patient starts. Investors who bought Ardelyx stock during this period may be entitled to compensation. Those interested in joining the lawsuit must act by November 16, 2026.
The news concerns Ardelyx, Inc. and a securities fraud lawsuit. For readers following the health sector, here is Pluang's market snapshot as of Sep 21, 2026 21:11 WIB: out of 95 priced US health stocks, 54 rose and 39 fell today. Notable movers include HIMS at USD 28.67 with a 1-day change of +2.43%, ACB at USD 3.96 with +2.33%, and AMPH at USD 24.16 with +2.29%.
Alkermes plc's drug ALKS7290 demonstrated significant improvement in ADHD symptoms in a Phase 1b trial, with patients showing a 14- to 19-point gain on a 54-point scale within two weeks. This outperforms typical placebo effects, which range from 6 to...
Morgan Stanley upgraded NNN REIT from Neutral to Overweight due to its stable income and strong financial health. The REIT boasts a 99.1% occupancy rate and 97.5% fixed-rate debt, ensuring steady rental income and protection against interest rate hik...
BlackBerry's stock rose 5% following a buy recommendation from Jim Cramer on CNBC, ahead of its quarterly earnings report scheduled for September 24. The rally is driven by optimism around BlackBerry's QNX software, which powers embedded systems in v...
Oklo, an advanced nuclear energy company, achieved a major milestone by reaching first criticality at its Groves reactor just over 11 months after groundbreaking, a feat unmatched by peers. Despite a 64% share price drop over the past year, the compa...
NVIDIA lost about $300 billion in market value after the Federal Reserve raised interest rates by a quarter point, pushing the 10-year Treasury yield near a 52-week high. This rate increase impacts NVIDIA heavily because its valuation depends on cash...
